Indeed, KIT, implicated in the human “Th2 high” asthma endotype, has recently been advocated as an appropriate therapeutic target molecule in cases of severe refractory asthma (e.g., imatinib or anti-KIT monoclonal antibodies) [46,47,52]. The gene discussed is KIT; the disease is asthma.